ReportGem ReportGem

U.S. COMPANY FILING

REGENERON PHARMACEUTICALS, INC. — Form 8-K filed 2026-01-30

Filed: 2026-01-30Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNExchange: NasdaqForm: 8-KReport period: 2026-01-30SEC accession: 0000872589-26-000004Event: earningsMateriality: 30

Filing text preview

Regeneron Pharmaceuticals filed a Form 8-K on January 30, 2026, announcing its fourth quarter and full year 2025 financial and operating results via a press release furnished as Exhibit 99.1. The information is furnished but not deemed filed. No specific financial figures were provided in the filing, so the event is a routine earnings disclosure with neutral impact.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-01-30Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-2010-Q2026-07-30 · 10-Q8-K2026-07-30 · 8-K10-Q2026-04-29 · 10-Q8-K2026-04-29 · 8-K10-K2026-02-04 · 10-K